中东和非洲翼状胬肉药物市场，按疾病类型（进行性翼状胬肉和萎缩性翼状胬肉）、分期（第 2 期、第 3 期、第 1 期、第 4 期）、治疗（人工泪液/外用润滑剂和类固醇眼药水）、配方（眼药水、眼药膏、其他）、购买方式（处方药和非处方药 (OTC)）、人群类型（老年人和成人）、最终用户（医院、专科诊所、家庭医疗保健、其他）、分销渠道（零售药店、医院药店、网上药店、其他）划分 - 行业趋势和预测到 2029 年。
市场分析和见解
翼状胬肉是一种常见的眼表病变，始于眼睑裂内的角膜缘，并进展至角膜。它以希腊语 pterygos 命名，意为“翅膀”。这种病变在鼻翼缘比颞侧更常见，具有典型的翼状外观。紫外线照射与翼状胬肉的发生密切相关。有高紫外线照射史和居住在赤道附近的人发病率较高（户外工作）。根据某些研究，男性发病率略高于女性，这可能是由于紫外线照射率较高。
它会导致眼睛发红、发炎和外观改变；它会导致散光，从而导致视力模糊；它还会导致白色或粉红色的肿块覆盖在眼睛前部。它可能影响一只眼睛或两只眼睛。
翼状胬肉的诊断是在全面眼科检查中使用显微镜检查眼睛的前部，并根据眼睛白色区域角膜上的组织生长情况进行。
Data Bridge Market Research分析，中东和非洲翼状胬肉药物市场在2022年至2029年的预测期内将以3.5%的复合年增长率增长。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020 (可定制至 2019-2014) |
|
定量单位 |
收入（百万美元），定价（美元） |
|
涵盖的领域 |
按疾病类型（进行性翼状胬肉和萎缩性翼状胬肉）、分期（第 2 期、第 3 期、第 1 期、第 4 期）、治疗方法（人工泪液/外用润滑剂和类固醇眼药水）、配方（眼药水、眼药膏等）、购买方式（处方药和非处方药 (OTC)）、人群类型（老年人和成年人）、最终用户（医院、专科诊所、家庭医疗保健等）、分销渠道（零售药店、医院药店、网上药店等） |
|
覆盖国家 |
南非、沙特阿拉伯、阿联酋、埃及、以色列、科威特以及中东和非洲其他地区 |
|
涵盖的市场参与者 |
Johnson & Johnson Services, Inc. (U.S.), Novartis AG (Switzerland), Akorn Operating Company LLC (U.S.), Bausch & Lomb Incorporated (Canada), AbbVie Inc. (U.S.), Prestige Consumer Healthcare Inc. (U.S.), Théa Laboratories (France), Wellona Pharma (India), Bayer AG (Germany), Zydus Group, Amneal Pharmaceuticals LLC (India), OASIS Medical (U.S.), Alcon (Switzerland), and Santen Pharmaceutical Co., Ltd. (Japan) |
Market Definition
Pterygium is a common ocular surface lesion that begins in the limbal conjunctiva within the palpebral fissure and progresses to the cornea. It is named after the Greek word pterygos, which means "wing". The lesion occurs more frequently at the nasal limbus than the temporal with a characteristic wing-like appearance. UV exposure is strongly linked to the occurrence of pterygia. Individuals having a history of elevated UV exposure and those living closer to the equator have a higher incidence (outdoor work). According to certain research, males have a somewhat higher incidence than females, which could simply be due to a higher rate of UV exposure.
Pterygium is diagnosed using a microscope to examine the front components of the eye during a full eye examination and based on the appearance of tissue growth on the cornea from the white area of the eye.
Middle East and Africa Pterygium Drug Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- The rise in incidences and prevalences of ophthalmic disorders
According to data published in the National Library of Medicine (National Center for Biotechnology Information) in 2021, the prevalence rates vary in different places. It is most abundant in Cameron's "pterygium belt," which runs between 37° north and south of the equator.
The most common causes of pterygium include long-term exposure to ultraviolet (UV) light from the sun (most common cause) and eye irritation caused by hot, dry weather, wind, and dust. The affirmative factors state that this is the major driver for the global pterygium drugs market.
- The rise in the geriatric population
With the growing geriatric population across the globe, the prevalence of ophthalmic diseases with severe ocular pain is also growing. According to a data provided published in "Global Prevalence of Blindness and Distance and Near Vision Impairment in 2020: progress towards the Vision 2020 targets and what the future holds" by "The Association for Research in Vision and Ophthalmology" (ARVO) estimated 41.9 million people were blind.
With the growing population, the pressure on the healthcare system is increasing. The demand for care and services is rising to treat the problem of Ophthalmol disorder, including pterygium. Therefore, the increasing geriatric population is a great opportunity for the Middle East and Africa pterygium drug market.
Opportunity
-
Programs and initiatives to reduce the burden of eye diseases
The International agency to prevent blindness has launched several programs and initiatives with well-reputed NGOs and corporates to spread awareness and reduce the burden of eye diseases.
For instance,
-
International Agency endorses our Children's Vision and an initiative co-founded by the Brien Holden Vision Institute and the Vision For Life fund (created by Essilor) for the Prevention of Blindness (IAPB)
Restraint/Challenge
The growing prevalence of various ophthalmic disorders has also increased the necessity for timely treatments. However, the treatments and proper medication for ophthalmology disorders are not very cheap. Recent studies show that the price of topical steroids price is increasing in the past few years. Even though some topical ophthalmic steroids like prednisolone are mildly cheap, other advanced medications and eye drops are still expensive.
Middle East and Africa pterygium drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pterygium drug market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.
Patient Epidemiology Analysis
The prevalence of ophthalmic disorders keeps showing a surge in growth due to the rise in chemical industries and pollution worldwide. Chemical burns and flash burns cause significant and severe ocular pain due to irritations over the eye surface.
According to data published in the National Library of Medicine (National Center for Biotechnology Information) in 2021, the prevalence rates vary in different places. It is most abundant in Cameron's "pterygium belt," which runs between 37° north and south of the equator. Pterygium prevalence has been reported to range from 0.3 to 29% worldwide.
Middle East and Africa pterygium drug market also provides detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence are some data variables available in the report. Direct or indirect impact analysis of epidemiology to the market growth are analyzed to create a more robust and cohot multivariate statistical model for forecasting the market in the growth period.
Post COVID-19 Impact on Middle East and Africa Pterygium Drug Market
COVID-19 has negatively affected the market. Lockdowns and isolations during pandemics complicate disease management and medication adherence. The lack of access to healthcare facilities for routine treatment and medication administration will further impact the market.
Recent Development
- In May 2022, Alcon announced the acquisition of EYSUVIS (loteprednol etabonate suspension) pharmaceutical eye drop from Kala Pharmaceuticals, Inc. The acquisition will complement the company's Systane family of eye drops, including preservative-free formulations.
Middle East and Africa Pterygium Drug Market Scope
Middle East and Africa pterygium drug market is categorized into eight notable segments based on disease type, stages, treatment, formulation, mode of purchase, population type, end-user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Progressive Pterygium
- Atrophic Pterygium
Based on disease, the Middle East and Africa pterygium drug market is segmented into progressive pterygium and atrophic pterygium.
Stages
- Stage 1
- Stage 2
- Stage 3
- Stage 4
Based on stages, the Middle East and Africa pterygium drug market is segmented into stage 1, stage 2, stage 3, and stage 4.
Treatment
- Artificial Tears/Topical Lubricants
- Steroid Eye Drops
Based on treatment, the Middle East and Africa pterygium drug market is segmented into artificial tears/topical lubricants, and steroid eye drops.
Formulation
- Eye Drops
- Eye Ointments
- Others
Based on formulation, the Middle East and Africa pterygium drug market is segmented into eye drops, eye ointments, and others.
Mode of Purchase
- Prescription
- Over the Counter (OTC)
Based on mode of purchase, the Middle East and Africa pterygium drug market is segmented into prescription and over-the-counter (OTC).
Population Type
- Geriatric
- Adults
Based on population type, the Middle East and Africa pterygium drug market is segmented into geriatric and adults.
End-User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Based on end-user, the Middle East and Africa pterygium drug market is segmented into hospitals, specialty clinics, home healthcare, and others.
Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Others
Based on distribution channels, the Middle East and Africa pterygium drug market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies.
Middle East and Africa Pterygium Drug Market Regional Analysis/Insights
Middle East and Africa pterygium drug market is analyzed, and market size insights and trends are provided by country, disease type, stages, treatment, formulation, mode of purchase, population type, end-user, and distribution channel. as referenced above.
The countries covered in the Middle East and Africa Middle East and Africa pterygium drug market report are South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait and Rest of Middle East and Africa.
Middle East and African pterygium drug market are expected to grow due to increased government initiatives to reduce the burden of eye illnesses.
South Africa is expected to dominate the Middle East and Africa pterygium drug market in terms of market share and market revenue. It will continue to flourish its dominance during the forecast period. This is due to the increasing awareness of early diagnosis and treatment of disease
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Pterygium Drug Market Share Analysis
Middle East and Africa pterygium drug market competitive landscape provides details of the competitor. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, European presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the pterygium drug market.
Some of the major players operating in the Middle East and Africa pterygium drug market are Johnson & Johnson Services, Inc., Novartis AG, Akorn Operating Company LLC, Bausch & Lomb Incorporated, AbbVie Inc., Prestige Consumer Healthcare Inc., Théa Laboratories, Wellona Pharma, Bayer AG, Zydus Group, Amneal Pharmaceuticals LLC, OASIS Medical, Alcon, and Santen Pharmaceutical Co., Ltd. among others.
Research Methodology
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、MEA 与区域以及供应商份额分析。如有进一步询问，请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 CLASS SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
4.3 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: NUMBER OF SURGERIES
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS
7 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: REGULATIONS
7.1 REGULATION IN THE U.S.
7.2 REGULATION IN EUROPE:
7.3 REGULATIONS IN CHINA:
7.4 REGULATIONS IN INDIA:
7.5 RELEVANT ACTS FOR THIS FRAMEWORK:
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISE IN INCIDENCES AND PREVALENCE OF OPHTHALMIC DISORDERS
8.1.2 RISE IN GERIATRIC POPULATION
8.1.3 INCREASE IN HEALTHCARE AWARENESS TO REDUCE THE RISK OF EYE ILLNESSES
8.2 RESTRAINTS
8.2.1 HIGH COST OF EYE TREATMENT AND MEDICATION
8.2.2 SIDE EFFECTS OF STEROIDS EYE DROPS
8.3 OPPORTUNITIES
8.3.1 PROGRAMS AND INITIATIVES TO REDUCE THE BURDEN OF EYE DISEASES
8.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
8.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES
8.4 CHALLENGES
8.4.1 STRINGENT RULES & REGULATIONS
8.4.2 EXPOSURE TO ULTRAVIOLET RADIATIONS
9 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 PROGRESSIVE PTERYGIUM
9.3 ATROPHIC PTERYGIUM
10 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY STAGES
10.1 OVERVIEW
10.2 STAGE 2
10.3 STAGE 3
10.4 STAGE 1
10.5 STAGE 4
11 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 ARTIFICIAL TEARS/TOPICAL LUBRICANTS
11.2.1 DEMULCENT
11.2.2 EMOLLIENTS
11.3 STEROID EYE DROPS
11.3.1 KETONE STEROIDS
11.3.1.1 PREDNOSOLONE
11.3.1.2 DEXAMETHASONE
11.3.1.3 FLUROMETHOLONE
11.3.1.4 OTHERS
11.3.2 ESTER STEROID (LOTERPREDNOL)
12 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY FORMULATION
12.1 OVERVIEW
12.2 EYE DROPS
12.2.1 EYE DROPS WITH PRESERVATIVES
12.2.2 PRESERVATIVE-FREE EYE DROPS
12.3 EYE OINTMENTS
12.4 OTHERS
13 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE
13.1 OVERVIEW
13.2 PRESCRIPTION
13.3 OVER THE COUNTER (OTC)
14 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY POPULATION TYPE
14.1 OVERVIEW
14.2 GERIATRIC
14.3 ADULTS
15 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CLINICS
15.4 HOME HEALTHCARE
15.5 OTHERS
16 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 RETAIL PHARMACIES
16.3 HOSPITAL PHARMACIES
16.4 ONLINE PHARMACIES
16.5 OTHERS
17 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY REGION
17.1 MIDDLE EAST AND AFRICA
17.1.1 SOUTH AFRICA
17.1.2 EGYPT
17.1.3 ISRAEL
17.1.4 UAE
17.1.5 SAUDI ARABIA
17.1.6 KUWAIT
17.1.7 REST OF MIDDLE EAST AND AFRICA
18 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
19 SWOT ANALYSIS
20 COMPANY PROFILES
20.1 ALCON
20.1.1 COMPANY SNAPSHOT
20.1.2 RECENT FINANCIALS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 ABBVIE INC.
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 BAUSCH & LOMB INCORPORATED
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 JOHNSON & JOHNSON SERVICES, INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 BAYER AG
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 NOVARTIS AG
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.7 SANTEN PHARMACEUTICAL CO., LTD.
20.7.1 COMPANY SNAPSHOT
20.7.2 RECENT FINANCIALS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.8 AKORN OPERATING COMPANY LLC
20.8.1 COMPANY SNAPSHOT
20.8.2 PRODUCT PORTFOLIO
20.8.3 RECENT DEVELOPMENT
20.9 AMNEAL PHARMACEUTICALS LLC.
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENTS
20.1 EYERIS VISIONCARE PVT. LTD.
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 MAYA BIOTECH PRIVATE LIMITED
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENTS
20.12 OASIS MEDICAL
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENTS
20.13 PRESTIGE CONSUMER HEALTHCARE INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENT
20.14 SAGER PHARMA
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENTS
20.15 SIMILASAN CORPORATION
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENTS
20.16 SPECTRA VISION CARE
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENTS
20.17 SYLENTIS
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENT
20.18 THÉA LABORATORIES
20.18.1 COMPANY SNAPSHOT
20.18.2 PRODUCT PORTFOLIO
20.18.3 RECENT DEVELOPMENTS
20.19 WELLONA PHARMA
20.19.1 COMPANY SNAPSHOT
20.19.2 PRODUCT PORTFOLIO
20.19.3 RECENT DEVELOPMENTS
20.2 ZYDUS GROUP
20.20.1 COMPANY SNAPSHOT
20.20.2 REVENUE ANALYSIS
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
表格列表
TABLE 1 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, PIPELINE ANALYSIS
TABLE 2 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA PROGRESSIVE PTERYGIUM IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA ATROPHIC PTERYGIUM IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET , BY STAGES, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA STAGE 2 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA STAGE 3 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA STAGE 1 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA STAGE 4 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA STEROID EYE DROPS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA STEROID EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA EYE DROPS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA EYE OINTMENTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA PRESCRIPTION IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA OVER THE COUNTER (OTC) IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA GERIATRICS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA ADULTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA HOSPITALS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA HOME HEALTHCARE IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA RETAIL PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA HOSPITAL PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA ONLINE PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 50 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 51 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 52 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 53 SOUTH AFRICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 SOUTH AFRICA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 SOUTH AFRICA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 57 SOUTH AFRICA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 58 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 59 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 60 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 61 SOUTH AFRICA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 62 EGYPT PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 63 EGYPT PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 64 EGYPT PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 65 EGYPT ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 EGYPT STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 EGYPT KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 EGYPT PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 69 EGYPT EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 70 EGYPT PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 71 EGYPT PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 72 EGYPT PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 73 EGYPT PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 74 ISRAEL PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 75 ISRAEL PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 76 ISRAEL PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 77 ISRAEL ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 ISRAEL STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 ISRAEL KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 ISRAEL PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 81 ISRAEL EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 82 ISRAEL PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 83 ISRAEL PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 84 ISRAEL PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 85 ISRAEL PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 86 UAE PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 87 UAE PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 88 UAE PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 89 UAE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 UAE STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 UAE KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 UAE PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 93 UAE EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 94 UAE PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 95 UAE PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 96 UAE PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 97 UAE PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 98 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 99 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 100 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 101 SAUDI ARABIA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 SAUDI ARABIA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 SAUDI ARABIA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 105 SAUDI ARABIA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 106 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 107 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 108 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 SAUDI ARABIA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 KUWAIT PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 111 KUWAIT PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 112 KUWAIT PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 113 KUWAIT ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 KUWAIT STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 KUWAIT KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 KUWAIT PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 117 KUWAIT EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 118 KUWAIT PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 119 KUWAIT PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 120 KUWAIT PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 121 KUWAIT PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 122 REST OF MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: DBMR POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: SEGMENTATION
FIGURE 11 ASIA-PACIFIC IS ANTICIPATED TO DOMINATE THE PTERYGIUM DRUG MARKET AND GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS AND RISE IN GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET FROM 2022 TO 2029
FIGURE 13 PROGRESSIVE PTERYGIUM SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET FROM 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET
FIGURE 15 AGEING POPULATION IN THE WORLD (IN MILLIONS)
FIGURE 16 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, 2021
FIGURE 17 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)
FIGURE 18 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY STAGES, 2021
FIGURE 21 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY STAGES, 2022-2029 (USD MILLION)
FIGURE 22 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY STAGES, CAGR (2022-2029)
FIGURE 23 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY STAGES, LIFELINE CURVE
FIGURE 24 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY TREATMENT, 2021
FIGURE 25 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY TREATMENT, 2022-2029 (USD MILLION)
FIGURE 26 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 27 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 28 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY FORMULATION, 2021
FIGURE 29 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY FORMULATION, 2022-2029 (USD MILLION)
FIGURE 30 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY FORMULATION, CAGR (2022-2029)
FIGURE 31 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY FORMULATION, LIFELINE CURVE
FIGURE 32 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, 2021
FIGURE 33 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
FIGURE 34 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, CAGR (2022-2029)
FIGURE 35 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 36 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, 2021
FIGURE 37 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION)
FIGURE 38 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, CAGR (2022-2029)
FIGURE 39 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 40 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY END USER, 2021
FIGURE 41 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 42 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY END USER, CAGR (2022-2029)
FIGURE 43 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 45 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 46 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 47 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET: SNAPSHOT (2021)
FIGURE 49 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET: BY COUNTRY (2021)
FIGURE 50 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET: BY COUNTRY (2022 & 2029)
FIGURE 51 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET: BY COUNTRY (2021 & 2029)
FIGURE 52 MIDDLE EAST AND AFRICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 53 MIDDLE EAST & AFRICA PTERYGIUM DRUG MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
